Last reviewed · How we verify

Epoetin alfa or Epoetin beta

Affymax · Phase 3 active Small molecule

Epoetin alfa or Epoetin beta is a Erythropoiesis-stimulating agent (ESA) Small molecule drug developed by Affymax. It is currently in Phase 3 development for Anemia of chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with HIV infection on antiretroviral therapy. Also known as: Epogen, Neorecormon.

Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells. Used for Anemia of chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with HIV infection on antiretroviral therapy.

At a glance

Generic nameEpoetin alfa or Epoetin beta
Also known asEpogen, Neorecormon
SponsorAffymax
Drug classErythropoiesis-stimulating agent (ESA)
TargetErythropoietin receptor (EPOR)
ModalitySmall molecule
Therapeutic areaHematology/Oncology
PhasePhase 3

Mechanism of action

Epoetin is a glycoprotein hormone that mimics endogenous erythropoietin, activating the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow. This stimulates proliferation, differentiation, and maturation of red blood cells, increasing hemoglobin levels and oxygen-carrying capacity. It is used to treat anemia in patients with chronic kidney disease, cancer chemotherapy-induced anemia, and other conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Epoetin alfa or Epoetin beta

What is Epoetin alfa or Epoetin beta?

Epoetin alfa or Epoetin beta is a Erythropoiesis-stimulating agent (ESA) drug developed by Affymax, indicated for Anemia of chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with HIV infection on antiretroviral therapy.

How does Epoetin alfa or Epoetin beta work?

Epoetin alfa/beta is a recombinant erythropoietin that stimulates red blood cell production by binding to erythropoietin receptors on bone marrow progenitor cells.

What is Epoetin alfa or Epoetin beta used for?

Epoetin alfa or Epoetin beta is indicated for Anemia of chronic kidney disease, Chemotherapy-induced anemia in cancer patients, Anemia in patients with HIV infection on antiretroviral therapy.

Who makes Epoetin alfa or Epoetin beta?

Epoetin alfa or Epoetin beta is developed by Affymax (see full Affymax pipeline at /company/affymax).

Is Epoetin alfa or Epoetin beta also known as anything else?

Epoetin alfa or Epoetin beta is also known as Epogen, Neorecormon.

What drug class is Epoetin alfa or Epoetin beta in?

Epoetin alfa or Epoetin beta belongs to the Erythropoiesis-stimulating agent (ESA) class. See all Erythropoiesis-stimulating agent (ESA) drugs at /class/erythropoiesis-stimulating-agent-esa.

What development phase is Epoetin alfa or Epoetin beta in?

Epoetin alfa or Epoetin beta is in Phase 3.

What are the side effects of Epoetin alfa or Epoetin beta?

Common side effects of Epoetin alfa or Epoetin beta include Hypertension, Thrombotic events (DVT, PE, stroke), Headache, Injection site reactions, Pure red cell aplasia (rare).

What does Epoetin alfa or Epoetin beta target?

Epoetin alfa or Epoetin beta targets Erythropoietin receptor (EPOR) and is a Erythropoiesis-stimulating agent (ESA).

Related